Antiplatelet Therapy in Cardiovascular Disease

Content: List of Contributors, viii  Foreword, xix  Preface, xxi   Section I: Platelet biology and pathophysiology   1 Platelet Pathophysiology and its Role in Thrombosis, 3  Paul A. Gurbel and Udaya S. Tantry   2 Platelet Receptors and Drug Targets: COX-1, 8  Thomas Hohlfeld and Karsten Schror   3 Platelet Receptors and Drug Targets: P2Y12, 14  Marco Cattaneo   4 Platelet Receptors and Drug Targets: GP IIb/IIIa, 21  Eliano Pio Navarese and Jacek Kubica   5 Platelet Receptors and Drug Targets: PAR1, Collagen, vWF, Thromboxane, and Other Novel Targets, 29  Ping Zhang, Lidija Covic, and Athan Kuliopulos   6 Role of Inflammation and Hypercoagulability in Thrombosis, 45  Paul A. Gurbel, Nachiket Apte, and Udaya S. Tantry    Section II: Platelet function tests   7 Light Transmission Aggregometry, 53  Paul A. Gurbel, Martin Gesheff, Kevin P. Bliden, and Udaya S. Tantry   8 Vasodilator-Stimulated Phosphoprotein (VASP) Assay, 58  Marc Laine, Franck Paganelli, and Laurent Bonello   9 VerifyNow P2Y12 and Plateletworks Assays, 65  Matthew J. Price, Nicoline J. Breet, and Jurrien M. ten Berg   10 Multiplate Analyzer, 82  Martin Orban and Dirk Sibbing   11 Shear Stress-Based Platelet Function Tests, 92  Nicoline J. Breet and Jurrien M. ten Berg   12 Thrombelastography and Other Novel Techniques, 102  Udaya S. Tantry, Vijay A. Doraiswamy, Glenn Stokken, Marvin J. Slepian, and Paul A. Gurbel    Section III: Antiplatelet pharmacology   13 Aspirin, 111  Karsten Schror and Thomas Hohlfeld   14 Cilostazol, 117  Seung-Whan Lee, Duk-Woo Park, and Seung-Jung Park   15 Abciximab, 125  J. Emilio Exaire and Jorge F. Saucedo   16 Tirofiban, 131  Marco Valgimigli, Arnoud W.J. van't Hof, and Christian Hamm   17 Eptifibatide, 142  Nevin C. Baker and Ron Waksman   18 Ticlopidine, 150  Fabiana Rollini, Francesco Franchi, Ana Muniz-Lozano, and Dominick J. Angiolillo   19 Clopidogrel, 160  Andrzej Budaj   20 Prasugrel, 166  Christoph Varenhorst, Anna Oskarsson, and Stefan James   21 Elinogrel, 173  Matthew J. Chung and Sunil V. Rao   22 Cangrelor, 180  Francesco Franchi, Fabiana Rollini, Ana Muniz-Lozano, and Dominick J. Angiolillo   23 Ticagrelor, 193  Anna Oskarsson, Christoph Varenhorst, and Stefan James   24 Thrombin Receptor Antagonists, 198  Flavio de Souza Brito and Pierluigi Tricoci    Section IV: Percutaneous Coronary Intervention and Antiplatelet Therapy   25 Dual Antiplatelet Therapy Prior to Percutaneous Coronary Intervention, 209  Fabio Mangiacapra, Annunziata Nusca, Rosetta Melfi, and Germano di Sciascio   26 Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation, 220  Joshua P. Loh and Ron Waksman   27 Antiplatelet Therapy for Patients with Acute Coronary Syndromes, 229  Michael A. Gaglia, Jr. and Ray V. Matthews   28 Antiplatelet Therapy in Stable Coronary Artery Disease, 237  Ana Laynez and Ron Waksman   29 Antiplatelet Therapy for Patients with Peripheral Arterial Disease, 245  Aung Myat, Yousif Ahmad, and Simon R. Redwood   30 Bleeding Risk and Outcomes of Patients Undergoing Percutaneous Coronary Intervention Treated with Antiplatelets, 253  Sa'ar Minha and Ron Waksman   31 Bleeding Definitions, 259  Sameer Bansilal, Deborah E. Aronson, and Roxana Mehran    Section V: Antiplatelet Responsiveness   32 Personalizing Antiplatelet Therapy, 269  Paul A. Gurbel, Young-Hoon Jeong, and Udaya S. Tantry   33 Aspirin Resistance, 277  Muthiah Vaduganathan and Eli I. Lev   34 Clopidogrel Resistance, 285  Udaya S. Tantry, Kevin P. Bliden, Talha Meeran, and Paul A. Gurbel   35 Genetics of Clopidogrel Poor Response, 293  Pierre Fontana and Jean-Luc Reny   36 Proton Pump Inhibitors and Clopidogrel, 300  Michael A. Gaglia, Jr   37 Other Drug Interactions with Clopidogrel, 306  Eric R. Bates   Index, 314